Search our Test Catalog. Specify what to search (name, test code, titles, everywhere) and how to search (begins with, contains)

Unit Code 81975:
UroVysion for Detection of Bladder Cancer

Print Friendly View
Print Page Email Page

Method Description

Urinary cells are harvested, fixed, and placed on a slide. The FDA-

approved Vysis UroVysion probe set, which contains fluorescently

labeled DNA probes specific to the centromeres of chromosomes

3, 7, and 17, and to the 9p21 locus is hybridized to the cells on the

slide. The slide is washed and counterstained with 4,6-diamidino-

2-phenylindole (DAPI). Fluorescence microscopy with unique band

filters is then used to scan the slide for atypical cells (eg, cells with

nuclear enlargement or irregularity). These cells are assessed for

gains of chromosomes (3, 7, 17) or homozygous 9p21 deletion. If the

number of cells with chromosomal gains (polysomy or trisomy) or

homozygous 9p21 deletion observed on scanning is sufficient to

consider the test result positive, the percentage of transitional cells

with polysomy, trisomy, or homozygous 9p21 deletion is determined.

(Halling KC, King W, Sokolova IA, et al:  A comparison of cytology

and fluorescence in situ hybridization for the detection of urothelial

carcinoma. J Urol 2000;164:1768-1775; Sokolova IA, Halling KC,

Jenkins RB, et al:  The development of a multi-target, multi-color

fluorescence in situ hybridization assay for the detection of urothelial

carcinoma in urine. J Mol Diagn 2000;2:116-123; Halling KC, King W,

Sokolova IA, et al:  A comparison of BTA stat, hemoglobin dipstick,

telomerase, and Vysis UroVysion assays for the detection of urothelial

carcinoma in urine. J Urol 2002; 167:2001-2006)

Performing Laboratory Location

Rochester

Key